Trial Profile
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 May 2022 Status changed from active, no longer recruiting to discontinued.
- 16 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2017 Status changed from not yet recruiting to recruiting.